Ensuring that intellectual property rights aren’t a barrier to scaling-up: the remarkable example of...
This week various international bodies are tackling different challenges in meeting the urgent problem of scaling-up manufacture of and access to vaccines for Covid-19....
The last mile: A few suggestions for the WHO Pandemic Agreement’s last two weeks...
This technical briefing note is also available as a PDF here.
On 16 April, the Bureau of the Intergovernmental Negotiating Body (INB) to draft and...
The Role of Activism in Shaping Law and Policies that Support Access to Medicines
This article is also available as a PDF here.
Almost 26 years ago, here in Amsterdam, on November 25-26, 1999, Health Action International, Médecins Sans...
Sharing know-how/trade secrets during a pandemic: We must be planning for it now
Medicines Law & Policy has recently proposed a provision for inclusion in the draft WHO pandemic instrument currently being discussed in Geneva (here and...
Never say never – Why the High Income Countries that opted-out from the Art....
To limit the ability of patent owners to charge excessive prices for patented medicines, countries can grant compulsory licences which permit others to produce...
WTO Covid-19 TRIPS Decision: Some observations
This morning, 17 June at 5 AM the 12th World Trade Organization (WTO) Ministerial Conference (MC12) approved a package of decisions and declarations. The...
Lessons for a pandemic preparedness treaty from previous successes and failures with treaty-based technology...
This post can also be downloaded as a PDF here.
1. Introduction
Scaling-up production of new vaccines to provide many billions of doses on a time-scale...
Continuing to ignore the problem of the know-how gap won’t make it go away.
The Covid-19 pandemic was a wake-up call for a variety of issues in access to medicines, one of which was finding a solution to...
Brazil’s Federal Court Reviews Medicines Mailbox Patents
This week the media reported that the Brazilian federal court removed the patent protection for eculizumab, sold under the brand name Soliris by Alexion...
Proposed TRIPS waiver a hollow diplomatic compromise with little practical impact
In October of 2020, 9 months into the pandemic, fearing conflicts over intellectual property (IP) related to medical measures to fight the pandemic, India...